T 1026/19 (Single dose administration/BOEHRINGER INGELHEIM) of 07.10.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:T102619.20221007
- Date of decision
- 7 October 2022
- Case number
- T 1026/19
- Petition for review of
- -
- Application number
- 11164850.7
- IPC class
- A61K 39/12
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
- Applicant name
- Boehringer Ingelheim Animal Health USA Inc.
- Opponent name
- Intervet International BV (opposition withdrawn)
Eli Lilly and Company - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 101European Patent Convention Art 113(2)
- Keywords
- Basis of decision - agreement to text withdrawn by patent proprietor
Basis of decision - patent revoked by opposition division
Basis of decision - appeal dismissed - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.